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ABSTRACT:  
 
Coffee consumption alters plasma lipid and cholesterol concentrations, however, its effects 
on lipoprotein(a) (Lp(a)) have received little study. The aim of this PRISMA compliant 
systematic review was to examine the role of coffee on serum Lp(a). 
This study was prospectively registered (PROSPERO 2015:CRD42015032335). PubMed, 
Scopus, Web of Science and Cochrane Central were searched from inception until 9th January 
2016 to detect trials and epidemiological studies investigating the impact of coffee on serum 
Lp(a) concentrations in humans. 
We identified six relevant publications describing nine experimental trials of various designs. 
There were a total of 640 participants across all studies and experimental groups. In short-
term controlled studies, consumption of coffee, or coffee diterpenes was associated with 
either a reduction in serum Lp(a) of 11 mg/dl (6 trials, 275 participants), or no effect (2 
trials, 56 participants). Conversely, one cross-sectional study with 309 participants showed 
serum Lp(a) was elevated in chronic consumers of boiled coffee who had a median Lp(a) of 
13.0 mg/dl (range 0-130) compared with consumers of filtered coffee who had median Lp(a) 
7.9 mg/dl (range 0-144) 
The effect of coffee on Lp(a) is complex and may follow a biphasic time-course. The type of 
coffee and the method of preparation appear to be important to determining the effect on 
Lp(a) 
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INTRODUCTION 
Coffee is a caffeine-containing beverage prepared as an aqueous extract of the beans of 
the Coffea plant. It is commonly consumed in Western society (Doepker et al. 2016). 
Previous meta-analyses have demonstrated associations between coffee consumption 
(particularly unfiltered coffee) and serum lipid concentrations (Jee et al. 2001). In particular, 
plasma concentrations of LDL-cholesterol and total cholesterol increase in a dose-dependent 
manner with exposure to coffee (Jee et al. 2001, Cai et al. 2012). Two diterpenes: kahweol 
and cafestol have been shown to be implicated in the lipid-modulating effects of coffee 
(Heckers et al. 1994, Weustenvanderwouw et al. 1994). These diterpenes are sometimes 
trapped by the paper filter used in some methods of coffee preparation. Scandinavian boiled 
coffee was shown to contain 3-4 mg of each diterpene per cup, compared with less than 
0.1mg of each diterpene when the coffee was filtered (Urgert et al. 1995, Urgert et al. 1997). 
This helps to explain the observation that different methods for brewing coffee result in 
different effects on serum lipids (Dusseldorp et al. 1991). 
Lipoprotein(a) (Lp(a)) particles consist of low-density-lipoprotein-like particles which 
are covalently bound to apolipoprotein(a) (Bos et al. 2014). Serum concentrations of 
lipoprotein(a) are positively correlated with cardiovascular risk (Kamstrup et al. 2009). 
Evidence from a study employing Mendelian randomization suggests that the link is causal 
(Kamstrup et al. 2009). A recent meta-analysis has demonstrated that elevated Lp(a) is an 
independent risk-factor for stroke (Nave et al. 2015). Low-fat diets that result in weight loss 
do not appear to result in alterations in plasma Lp(a) and two comprehensive reviews have 
concluded that the effects of diet on plasma Lp(a) concentrations are negligible (Puckey et al. 
1999, Bos et al. 2014). Nevertheless, the well documented lipid-modulating effects of coffee, 
and the increasing recognition of Lp(a) as a risk factor for cardiovascular disease warrant 
investigation as to whether coffee can modulate plasma concentrations of Lp(a). It was our 
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intention to carry out a systematic review and meta-analysis of studies of randomized 
controlled trials investigating the effect of coffee consumption on plasma Lp(a) 
concentrations in humans.  
Our extensive and systematic literature search uncovered a limited, but interesting body 
of knowledge on this topic. There were insufficient randomised-controlled trials to perform a 
meta-analysis, so, instead we summarised in narrative format all the available evidence from 
studies in humans.  
 
METHODS 
Registration and search strategy 
This PRISMA compliant study was prospectively registered (PROSPERO 2015: 
CRD42015032335). PubMed, Scopus, Web of Science and Cochrane Central were searched 
from inception until 9th January 2016. All fields were searched for the terms: (coffee OR 
"coffee" OR coffee* OR caffeine OR caffeine* OR "caffeine") AND (lipoprotein a OR LPa 
OR LP(a) OR lipoprotein(a) OR lipoprotein(a). Additionally, in the PubMed database, the 
terms were searched as MESH headers and all subheadings were included in the searches. 
 
Inclusion and Exclusion Criteria 
Inclusion Criteria 
This systematic review included all studies in humans that examined the relationship 
between the consumption of coffee (or extracts of coffee) upon plasma concentrations of 
Lp(a). The PICOS strategy is outlined in Table 1. When results of a study were reported 
more than once, the most recent or complete article, or the one with the largest sample size, 
was included. 
The following criteria were applied for inclusion: 
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 Controlled trials or crossover trials which reported serum Lp(a) concentration at the 
baseline and completion and included coffee consumption (or abstinence) as an 
intervention (and studies from which these data were not reported but could be 
obtained from the study authors) 
 Prospective cohort studies or other epidemiological studies which reported serum 
lipoprotein(a) concentrations and coffee consumption (and studies from which these 
data were not reported but could be obtained from the study authors) 
Exclusion Criteria 
Studies which were not conducted in humans were excluded. Studies which did not enable us 
to obtain sufficient information regarding Lp(a) were also excluded, except when that 
information could be obtained from study investigators. 
 
Study Selection 
All relevant articles were independently reviewed by two investigators (PP & MCS). The 
above inclusion and exclusion criteria were used to evaluate each article for selection into the 
systematic review. A third investigator (SU) was consulted to resolve study inclusion and 
exclusion discrepancies.  
 
Data extraction  
Eligible studies were reviewed and the following data were abstracted: first author's 
name; year of publication; country were the study was performed; study design; number of 
participants (divided into experimental groups where appropriate); details of coffee 
intervention; age, gender and body mass index (BMI) of the participants; baseline systolic 
and diastolic blood pressures; baseline TC, HDL-C, LDL-C and TG; baseline and (where 
appropriate) follow-up values of plasma concentrations of Lp(a). Studies reported their 
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results in a variety of units. Where the units for lipids given in the units mmol/l they were 
converted to mg/dL by multiplying by the following conversion factors (HDL-C, 38.61; 
LDL-C, 38.61; TC, 38.61; Triglycerides, 88.50). Data extraction was carried out by two 
investigators (PP & CS) 
Quality Assessment 
In order to assess the risk of bias in trials included in this review, the Cochrane 
Collaboration’s tool for assessing risk of bias in randomized studies was used (Higgins et al. 
2011, Higgins et al. 2011). Appropriate sections of this tool were completed for the one 
cross-sectional study. No trials, which met the inclusion criteria, were excluded from the 
systematic review on quality grounds. 
 
RESULTS 
Search results and trial flow 
The flow of papers through the process is shown in Figure 1. Our searches found 945 
papers. An initial screen of titles and abstracts was performed in order to remove articles, 
which were clearly irrelevant. After reading the full-texts of the remaining 121 papers, we 
identified 6 relevant papers (Urgert et al. 1996, Urgert et al. 1997, Strandhagen et al. 2003, 
Yukawa et al. 2004, Bukowska et al. 2006, Correa et al. 2013).  
 
Description of studies 
The characteristics of the studies and their participants and methods of the relevant 
papers we found are summarized in Table 2.  The methods employed in the studies were 
extremely diverse The Quality assessment is shown in Table 3. The papers were published 
between 1996 and 2013 and included one relevant epidemiological study and five 
experimental papers describing nine trials of various designs. There were a total of 640 
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participants across all studies and experimental groups. Included in these figures are studies, 
which did not report the effect of coffee on Lp(a) quantitatively, but where that data was 
kindly provided by the authors. The studies included crossover and parallel group designs as 
well as trials in which participants were followed through a time course of coffee 
consumption and coffee abstinence. Interventions included boiled and filtered coffee and 
coffee diterpenes dissolved in oil. Comparators included abstinence from coffee, alternative 
methods of coffee consumption and placebo oil, or oil stripped of diterpenes. The effects of 
coffee consumption upon plasma Lp(a) are summarized in Table 4. 
 
DISCUSSION  
With respects to the methods employed, the studies were very heterogeneous. In studies 
where two blends of coffee were prepared, masking of participants to the blend was possible; 
in other circumstances masking the coffee intervention would have been extremely difficult 
and was not attempted. Nevertheless, it is unlikely that a participant’s knowledge of their 
intervention would affect their plasma Lp(a) in a manner that would introduce bias. The 
difficulty of producing a placebo alternative to coffee may explain the paucity of randomized 
placebo controlled parallel group studies.  
Urgert et al. published a paper that reported the results of four clinical trials(Urgert et al. 
1997). They called these: Trial A, Trial B, Trial C and Trial D (Urgert et al. 1997). All were 
of relevance to this systematic review, and together provide information about the magnitude 
and direction of the effect of coffee on Lp(a), and also the components within coffee 
responsible for these effects. Trial B and Trial C were randomised placebo-controlled trials, 
Trials A and D had alternative study designs.  
‘Trial A’ which was designed to compare the effects on Lp(a) of diterpene-rich unfiltered 
coffee with filtered coffee (Urgert et al. 1997). After a run-in period of four weeks in which 
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the participants drank filtered, coffee, they were randomised to receive 0.9 l/day (5 cups) of 
either filtered coffee or cafetiere coffee (Urgert et al. 1997). The concentrations of the 
diterpenes in the coffee were measured and translated in to daily doses (Urgert et al. 1997). 
Filtered coffee provided less than 1mg/day of each diterpene. Cafetiere coffee provided 38 
mg/day cafestol and 33mg/day kahweol. Repeated measurements of Lp(a) were taken over 
time. Cafetiere coffee produced a fall in Lp(a) which was maximal at 8 weeks (1.5 mg/dL) 
and which stabilized at around 0.5 mg/dL between weeks 12 and 24 (Urgert et al. 1997). This 
time course may be of interest in explaining the results of an epidemiological study, 
described later, in which coffee consumption was associated with elevated Lp(a). 
In Trial B, Urgert et al. performed a double-masked randomised-controlled trial in which 
32 participants were randomised to receive 3g/day of either placebo oil (a 3:2 w/w mixture of 
sunflower oil and palm oil) or coffee oil which gave a daily dose of 85 mg of cafestol and 
103 mg of kahweol(Urgert et al. 1997). The intervention was administered for four weeks, 
after which a statistically significant difference was found between the two groups, with 
respect to Lp(a) concentrations which  were lower by a median of 5.3 mg/dL in the coffee oil 
group than in the placebo oil group (Urgert et al. 1997). Whilst these results seem to 
demonstrate a clear effect of coffee diterpenes on Lp(a), it should be noted that the daily 
doses of diterpenes are rather high, compared to that which might be expected from dietary 
coffee consumption. Another study reported in the same paper the authors found that 0.9 l of 
cafetiere coffee provided a dose of 38 mg cafestol and 33 mg kahweol (Urgert et al. 1997). 
Also reported in the same paper was ‘Trial C’ which used very similar methods to ‘Trial 
B’ and was also conducted over four weeks (Urgert et al. 1997). The 36 participants were 
randomised to receive 2g/day of placebo oil, coffee oil (equivalent to a daily dose of 57 mg 
cafestol and 69 mg kahweol), or coffee oil that had been stripped of cafestol and kahweol 
(Urgert et al. 1997). Coffee oil reduced LP(a) concentrations by 3.1 mg/dL, an effect that was 
9 
 
not seen with placebo oil or stripped oil (Urgert et al. 1997). These trials, although small, 
provide evidence that diterpenes are responsible for the acute effects of coffee consumption 
upon Lp(a) (Urgert et al. 1997). 
Further insight into the agent responsible for the acute Lp(a)-lowering effects of coffee 
was provided by Trial D (Urgert et al. 1997). Participants received either a mixture of 
cafestol (60 mg/day) and kahweol (48-54 mg/day) dissolved in placebo oil, or cafestol alone 
(61-64 mg cafestol/day and ≤ 1mg/day kahweol). After a seven-week washout period, during 
which they took placebo oil, they were crossed-over to the other treatment group (Urgert et 
al. 1997). Cafestol alone produced a reduction in Lp(a) of 3.5 ±0.8 mg/dL (mean ±S.D.) 
compared with 3.9 ± 1.0 for the mixture. The changes from baseline were statistically 
significant, but the differences between the groups were not. This suggests that cafestol is the 
major diterpene involved in Lp(a) reduction observed with acute consumption of coffee 
(Urgert et al. 1997). The results of this trial are interesting, but should be treated with caution, 
because of the small number of participants (5 in each group), and because two participants in 
treatment groups were switched to placebo after having elevated alanine amino transferase 
which exceeded the safety limits defined by the investigators. 
By combining data from all four of their randomised controlled trials. Urgert et al. made 
the interesting observation that the initial concentration of Lp(a) in an individual appears to 
influence the responsiveness of Lp(a) to coffee (or diterpene) treatment. After pooling the 
data, the investigators stratified participants into tertiles according to baseline Lp(a). Those 
with the highest initial values of Lp(a) saw the largest absolute reductions after treatment. 
Coffee or diterpenes treated participants in the highest baseline Lp(a) saw a median change in 
Lp(a) of -6.5 mg/dL, compared with control participants in the same Lp(a) tertile. For the 
middle Lp(a) tertile, the median difference was -3.3  mg/dL, and for the lowest tertile, -0.3 
mg/dL (Urgert et al. 1997). 
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Whilst Urgert et al. had found no effect of filter coffee upon Lp(a) (Urgert et al. 1997), a 
later study by Strandhagen and Thelle demonstrated an increase in Lp(a) after four weeks of 
consumption of 600 mml filter coffee per day (Strandhagen et al. 2003). The study consisted 
of two four-week periods of coffee consumption and two three-week periods of coffee 
abstention (Strandhagen et al. 2003). During both coffee consumption periods, Lp(a) values 
were reduced In the first period, the median difference was -11 mg/dl, in the second period it 
was -4 mg/dl (Strandhagen et al. 2003).The authors described the results as inconsistent, 
because there was no change in Lp(a) during the first abstention period, but a median increase 
of 15 mg/dl during the second abstention period. By comparison, total cholesterol increased 
during both the consumption periods and decreased during both the abstention periods 
(Strandhagen et al. 2003). Nevertheless, given the relatively small number of participants, the 
large variation in baseline Lp(a) levels between individuals, this would appear to be 
interesting evidence of a Lp(a)-lowering effect of filtered coffee (Strandhagen et al. 2003). 
Also employing filtered coffee, Correa et al. conducted a randomised crossover trial 
designed to compare the effects of medium roast coffee and medium light roast coffee on 
lipids and other biomarkers (Correa et al. 2013). The twenty participants drank three or four 
cups daily of the first roast, before switching over to the other type. The diterpene 
concentrations of the coffee were measured and, concentrations of cafestol were substantially 
higher than those seen in other studies employing filtered coffee (Correa et al. 2013). 
Medium light roast provided 5.36 mg cafestol and 0.79 mg kahweol per 150 mg cup; medium 
roast provided 6.3 mg cafestol and 0.51mg kahweol per 150 mg cup. Mean coffee 
consumption was 462 ml/day, equivalent to a daily dose of cafestol of approximately 20mg 
(Correa et al. 2013). There were no statistically significant changes in plasma Lp(a) 
throughout the trial. However the small sample size of the trial may have rendered it 
underpowered to detect differences in Lp(a). It is also possible that the relatively low cafestol 
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dose in this trial may have been insufficient to have an effect on Lp(a), although the trial did 
show interesting differences in cholesterol and biomarkers of inflammation. Importantly this 
study demonstrates that diterpenes are not always retained by a paper filter (Correa et al. 
2013). 
In a randomised double-masked crossover trial, Bukowska et al. compared “natural 
unfiltered” coffee and coffee “modified by water and pressure extraction” with intervention 
periods of 28 days (Correa et al. 2013). The study included 36 healthy volunteers and 
compared Lp(a) before and after the intervention. The authors found no statistically 
significant differences in mean Lp(a) for either form of coffee (Lp(a) before ‘modified form’ 
coffee 32 ± 24 mg/dL, after 38 ± 26 mg/dL; before ‘natural coffee 31 ± 27 mg/dL, after 32 ± 
28 mg/dL). The study did, however show an increase in homocysteine in participants 
drinking the “natural unfiltered coffee”, however the variance in baseline homocysteine was 
much smaller that for Lp(a), thus the trial may have been underpowered to detect changes in 
Lp(a) (Bukowska et al. 2006). 
Yukawa conducted a study in 11 healthy male students in which participants drank 150 
ml coffee three times per day for a week, preceded and followed by abstinence periods in 
which they drank only mineral water (Yukawa et al. 2004). The study aimed to investigate 
the effects of coffee on lipid metabolism and the oxidative modification of LDL-C. There 
were no differences between serum Lp(a) concentrations at the end of the baseline period 
(25.1± 16.2 mg/dL), the end of the coffee consumption period (23.2 ± 11.4 mg/dL), and the 
washout period (23.7 ± 13.9 mg mg/dL) (Yukawa et al. 2004). It is likely that this trial was 
underpowered to detect differences in Lp(a) over the time period employed, however, 
statistically significant decreases in TC and LDL-C were observed (Yukawa et al. 2004). The 
authors suggested that the relatively high dose of coffee used in this study (150 ml three times 
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a day) may explain the fact that opposite effects of coffee on TC and LDL-C were seen here, 
compared to other studies (Yukawa et al. 2004). 
Urgert et al. conducted a cross-sectional study comparing serum concentrations of Lp(a) 
in 150 habitual consumers of boiled coffee and 159 consumers of filter coffee (Urgert et al. 
1996). Participants aged 40-42 years who reported drinking five or more cups of coffee per 
day were included in the analysis. Higher plasma concentrations of Lp(a) were found in 
consumers of boiled coffee (median 13.0 mg/dL; range 0-130 mg/dL) than in those who 
drank filter coffee (median 7.9 mg/dL; range 0-144 mg/dL). There was evidence of a dose-
response relationship between boiled coffee consumption and Lp(a). The subset of boiled 
coffee drinkers who reported consuming nine or more cups of coffee per day had a median 
Lp(a) concentration of 13.6 mg/dL compared with 11.7 mg/dL for those who drank fewer 
than nine cups. For filter coffee the values were 8.0 mg/dL; and mg/dL (Urgert et al. 1996). 
Despite the fact that these results seem to be in opposition to those reported in experimental 
studies, they are convincing because of the relatively large number of participants and 
because the results appear to show a dose-response relationship between coffee and Lp(a). 
These results cannot demonstrate causality, nor can they tell us whether the same chemical 
components of coffee are responsible for the short term reduction, and the long term 
elevation of Lp(a), however the fact that consumers of filtered coffee had lower Lp(a) than 
consumers of boiled coffee, suggests the responsible component may be trapped in a filter in 
the same way as the diterpenes have been in some studies. 
In seeking to explain this result, the authors referred to previous observations that coffee 
increases serum alanine aminotransferase acutely. This marker is also elevated in liver 
disease (Weustenvanderwouw et al. 1994, Vanrooij et al. 1995). The investigators suggested, 
therefore, that in the short term diterpenes may disturb hepatocyte integrity, an effect which 
would be expected to result in reduced circulating Lp(a) (Gregory et al. 1994, Vanwersch 
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1994). Because normal serum concentrations of alanine aminotransferase were seen in this 
study, it was proposed that adaption occurs when coffee is consumed chronically. How and 
when this adaption occurs is unclear. This result is interesting in light of ‘Trial A’ described 
above, Urgert et al. reported maximal Lp(a) reduction after 8 weeks of consumption of boiled 
coffee,  with a much smaller reduction from baseline seen thereafter (Urgert et al. 1997). The 
time-course demonstrated in that experiments supports the hypothesis that acute and chronic 
exposure to coffee may have different effects on Lp(a). 
 
Clinical implications 
No clinical recommendations can be made based upon the current evidence. The possible 
biphasic effect of coffee on Lp(a) mean that whilst coffee may have a short term beneficial 
effect in reducing Lp(a), in the longer term it may prove to be detrimental. Furthermore, 
seemingly beneficial effects of coffee in reducing plasma Lp(a) are likely to be counteracted 
by the effects of coffee consumption at increasing plasma total cholesterol and low-density-
lipoprotein cholesterol which have been observed in most trials. Additionally, whilst elevated 
serum concentrations of Lp(a) are correlated with increased incidence of cardiovascular and 
cerebrovascular disease, the therapeutic benefit of Lp(a)-lowering is less well understood. 
Lp(a) should be more frequently measured and reported in clinical trials to enable us better to 
understand its prognostic importance, and to learn how it is affected by dietary and 
pharmacological interventions. Of the 106 papers selected for full-text screening but rejected 
for not reporting Lp(a), almost all reported numerous other lipid parameters. 
 
Limitations 
A limitation of this systematic review is the heterogeneity of study designs and 
interventions we included. Because of the small number of trials investigating the effects of 
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coffee consumption on Lp(a), we included all types of study design which included humans. 
The number of participants in trials was generally very small. With respect to the 
intervention, coffee came from a variety of sources and multiple methods of preparation were 
employed. Therefore the results are hard to assimilate, and it was not possible to perform a 
meta-analysis. Despite the heterogeneity in reported methods of coffee preparations 
examined, there is a lack of data regarding decaffeinated coffee and coffee produced by 
automated coffee machines. 
Heterogeneity of baseline serum concentrations of Lp(a) was noted within and between 
trials. The variability in this parameter is likely to increase the sample size required to 
demonstrate statistically significant changes with treatment. Additionally dietary 
interventions are harder to control than pharmaceutical intervention, adding another source of 
variability between participants. Thus trials which showed no effect of coffee on Lp(a) 
(Yukawa et al. 2004, Bukowska et al. 2006, Correa et al. 2013) or which showed an 
equivocal effect (Strandhagen et al. 2003) may have been underpowered with respect to 
Lp(a), despite being able to demonstrate changes in other parameters with baseline values 
which displayed less variance. 
All the studies included in this systematic review relied on participants accurately 
reporting their dietary habits, or carefully following instructions regarding coffee preparation 
and consumption. This is a methodological weakness of any research investigating diet, 
however there is no reason to suppose that incorrect reporting by participants would 
systematically bias the study, rather than increasing variance in all groups. 
The majority of the trials were not placebo controlled. Clearly it is clearly difficult to 
provide a placebo for coffee, without prior knowledge of the active Lp(a)-modifying agent. 
Even with this knowledge, it would be hard to produce a placebo whilst being certain that the 
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difference could not be detected by taste. Several of the trials could have been made more 
rigorous by parallel comparison of coffee-consuming groups and abstaining groups. 
 
CONCLUSIONS 
The effects of coffee consumption on plasma Lp(a) are complex and are likely to be 
affected by the baseline Lp(a) concentration, the source of the coffee, the method of 
preparation, the dose and the duration of consumption. There is a trend towards Lp(a)-
lowering effects of short-term consumption, with increased Lp(a) seen in chronic coffee 
drinkers.  There is a need for more widespread reporting of Lp(a) in clinical trials.  
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 Table 1. Description of the PICOS criteria used to define the research question 
Parameter Description 
Population Humans, without any restrictions. 
Intervention Coffee consumption, ingestion of coffee-derived products, abstinence from coffee in habitual consumers 
Comparator Placebo or abstinence from coffee consumption. 
Outcome Change in plasma concentration of lipoprotein(a) after intervention 
Study Design All study designs in humans. 
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Table 2. Design of the studies selected for analysis and demographic characteristics and baseline parameters of participants.  
Study Bukowska et 
al.  
Correa et al.  Strandhagen et 
al.  
Urgert et al.  Urgert et al.  
Trial A 
Urgert et al.  
Trial B 
Urgert et al.  
Trial C 
Urgert et al.  
Trial D 
Yukawa et 
al. 
(Yukawa et 
al. 2004)  
Publication 
Year 
2006 2013 2003 1996 1997 1997 1997 1997 2004 
Location Poland Brazil Sweden Norway The 
Netherlands 
The 
Netherlands 
The 
Netherlands 
The 
Netherlands 
Japan 
Design Randomised 
placebo 
controlled 
crossover trial 
Crossover 
Clinical Trial 
Controlled 
Study 
Cross-
Sectional 
Study 
Randomised 
Controlled 
Trial 
Randomised 
Controlled 
Trial 
Randomised 
Controlled 
Trial 
Randomised 
Controlled 
Crossover 
Trial 
Controlled 
Study 
Comparison Natural coffee 
vs pressure 
extracted 
modified 
coffee 
Medium roast 
coffee vs 
medium light 
roast 
Filtered coffee 
vs abstinence 
Boiled coffee 
drinkers vs 
filter coffee 
drinkers 
Filtered coffee 
vs Cafetiere 
coffee 
Placebo oil vs 
coffee oil 
Placebo oil vs 
coffee oil v 
‘stripped oil. 
Cafestol vs 
cafestol & 
kahweol 
Coffee vs 
abstinence 
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Trial 
Protocol 
4 weeks of first 
intervention; 
28 day break; 4 
weeks second 
intervention 
1 week run-in; 4 
weeks first 
intervention; 4 
weeks second 
intervention 
2 x (3 weeks 
abstinence, 4 
weeks 
consumption) 
NA 4 weeks filter 
coffee; 24 
weeks 
randomised 
intervention; 
12 weeks 
follow up 
2 weeks 
placebo oil; 4 
weeks 
randomised 
intervention; 
4 weeks 
follow up 
1 week placebo 
oil; 4 weeks 
randomised 
intervention; 4 
weeks follow 
up. 
2 x (2 week 
placebo oil; 4 
weeks 
randomised 
intervention, 7 
weeks follow 
up) 
1 week 
baseline, 1 
week 
coffee, 1 
week 
washout 
Inclusion 
criteria 
Healthy 
participants at 
age 28-55 
years (50% 
smokers). The 
study was 
conducted in 
the summer 
months to 
avoid vitamin 
deficiencies.   
Age 20 y to 65 y, 
plasma 
cholesterol <240 
mg/dl∞, blood 
glucose <5.56 
mmol/L, 
nonsmoker or 
former 
smoker (>2 y), 
alcohol 
consumption less 
than one drink 
Inclusion 
criteria were 
age 
range 30–65 y, 
free of 
clinically 
recognized 
chronic 
diseases 
such as 
cardiovascular 
diseases, 
Recruited as 
part of the 
Norwegian 
National 
Health 
Screening in 
1992, a 
population. 
Aged 
40–42 years 
Subjects were 
considered 
N/A N/A N/A N/A N/A 
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per day, absence 
of chronic 
diseases, and no 
use of regular 
medication 
cancer, renal 
disorders, liver 
disease and 
diabetes 
mellitus. They 
were not on 
antiepileptic 
or cholesterol-
lowering drugs, 
had been using 
coffee on a 
regular basis 
for at least 5y 
and were 
currently 
nonsmokers 
(at least for the 
last 6 months) 
eligible if 
they were 
healthy, did 
not take 
any 
medication 
known to 
affect liver 
enzymes or 
serum lipids, 
and did not 
consume 
more than 
three 
alcohol-
containing 
beverages per 
day 
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Source and 
type of 
coffee 
Two 
commercially 
available 
blends: natural 
coffee (MK 
Cafe – 100% 
Arabica) 
vs. modified 
coffee with 
60% less 
quantity of 2-
methylisoborneol 
(MK Cafe 
Feelings; both: 
MK Cafe, 
Poland) 
Two 
commercially 
available blends 
(80% Coffee 
Arabica L. cv. 
Bourbon and 
20% C. 
canephora cv. 
Robusta) of 
caffeinated, 
roasted, ground 
coffee 
Not stated, but 
provided by 
investigators to 
ensure 
consistency 
N/A Roodmerk 
(Douwe 
Egberts) a 
blend of 
Arabica and 
Robusta beans 
N/A N/A N/A Arabica 
coffee 
(Ajinomoto 
General 
Foods, 
Inc., Japan) 
Methods of 
coffee 
preparation 
Natural coffee 
vs pressure 
extracted 
Filtered Filtered N/A Filtered or 
Cafetiere 
Oil Oil Oil Coffee 
dissolved 
in boiling 
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coffee water 
Dose of 
coffee 
3 x 180 ml 
daily. Each 
serving 
prepared with 
13g ground 
coffee 
3-4 x 150 ml 
cups of coffee 
per day:  mean 
482 ± 61 ml/day 
600ml/day NA. 
Participants 
who 
habitually 
consumed 
five or 
more cups of 
boiled coffee 
per day were 
compared 
with matched 
filter coffee 
consumers 
Filtered coffee 
(0.9 L/day) 
Placebo oil 
(3g/day) 
Placebo oil 
(2g/day) 
Cafestol 150 ml 
three times 
per day 
Each 
serving 
prepared 
with 8g 
coffee. 
 
Coffee oil 
(2g/day) 
Cafestol + 
kahweol 
Stripped oil 
(2g/day) Cafetiere 
coffee (0.9 
L/day) 
Coffee oil 
(3g/day) 
Daily 
Cafestol 
dose (mg) 
N/A Approx 20  Not reported N/A <1 (filtered) 0 (placebo 
oil) 
0 (placebo) 61-64 
(Cafestol) 
N/A 
57 (coffee oil) 
38 (Cafetiere) 85 (coffee oil Not reported 
(stripped oil) 
60 (cafestol 
plus kahweol) 
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Daily 
Kahwol 
dose (mg) 
N/A Approx 2.5 Not reported N/A <1 (filtered) 0 (placebo oil 0 0-1 (Cafestol) N/A 
69 
33 (cafetiere 103 (coffee 
oil) 
Not reported 
(stripped oil) 
48-56 
(cafestol plus 
kahweol) 
Participants 36 20 120 (first trial 
period); 116 
(second trial 
period) 
150 (boiled) 24 (filtered) 16 (placebo 
oil) 
15 (placebo 
oil) 
10 (cafestol) 11 
15 (coffee oil) 
159 (filtered) 22 (cafetiere) 16 (coffee 
oil) 
16 (stripped 
oil) 
10 (cafestol 
plus kahweol) 
Age (years) 42.7±5.8 49±9 48.6 (29-65) 41 ± 1 
(boiled) 
29 ± 10 22 ± 2 22 ± 2 24 ± 4 Range 21-
31 
41 ± 1 
(filtered) 
Male (%) 44 30 
 
22 52.7 (boiled) 48.9 46.9 58.3 100 100 
55.3 (filtered) 
BMI 
((kg/m2) 
24.3±2.5 27.0±3.8 25.7 ± 3.4 25 ± 4 
(boiled) 
22 ± 3 22 ± 2 22 ±2 21 ±2 NS 
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25 ± 3 
(filtered) 
SBP 
(mmHg) 
N/A 110.2 ± 9.2 125.6 ± 17.3 N/A N/A N/A N/A N/A N/A 
N/A 
DBP 
(mmHg) 
N/A 70.5 ± 6.9 78.8 ± 11 N/A N/A N/A N/A N/A N/A 
N/A 
TC (mg/dL) 226 ± 35 
(Modified) ∞ 
186 ± 23 ∞ 201 ± 36 ∞ 231 ± 42 ∞ 
(boiled) 
189 ± 27 ∞ 174 ± 19 ∞ 174 ± 28 ∞ 186 ± 35 ∞ 185 ± 18  
221 ± 37 
(Natural) ∞ 
219 ± 41 ∞ 
(filtered) 
HDL-C 
(mg/dL) 
57 ± 11 
(Modified) ∞ 
 
46 ± 12 ∞ 56 ± 15 ∞ N/A 58 ± 12 ∞ 58 ± 12 ∞ 54 ± 12 ∞ 58 ±15  ∞ 57 ± 13 
53 ± 11 
(Natural) ∞ 
N/A 
LDL-C 
(mg/dL) 
125 ± 34 
(Modified) ∞ 
120 ± 19 ∞ N/A N/A 116 ± 31 ∞ 97 ± 19 ∞ 104  ± 23 ∞ 116 ± 27 ∞ 122 ± 25 
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127 ± 38 
(Natural) ∞ 
N/A 
TG (mg/dL) 123 ± 62 
(Modified) ∞ 
 
97 ± 35 110 ± 67 ∞ 190 ± 137 ∞ 
(boiled) 
97 ± 35∞ 89 ± 27 ∞ 79 ± 27 ∞ 71 ± 18 ∞ 93 ± 31 
129 ± 64 
(Natural) ∞ 
170 ±110 ∞ 
(filtered) 
Lp(a) 
(mg/dl) 
32 ± 24 
(Modified) 
22 ± 26 
(median = 11.5) 
NS NA 20.8 ± 22.3 
(median = 9.2) 
(filtered 
coffee) 
25.9  ± 23.8 
(median = 
17.2) 
(placebo oil) 
 
 24.4 ± 23.4 
(median =17.7) 
(placebo oil) 
13.9 ± 7.5 
(median 
=11.5) 
(cafestol) 
25.1 ± 16.2 
31±27 
(Natural) 
15.2 ± 19.9 
(median=9.8) 
(cafetiere 
coffee) 
29.1 ± 32.7 
(median 
=14.9) 
(coffee oil) 
 
16.6 ± 16.6 
(median =9.2) 
(coffee oil) 
13.9 ± 7.5 
11.5 (median)  
(cafestol + 
kahweol) 22.1 ± 25.5 
(median =12.8) 
(stripped oil) 
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Values are expressed as mean±SD unless otherwise stated ; ∞ values converted to units expressed here using http://www.endmemo.com/medical/unitconvert/ 
 
Abbreviations: SD: standard deviation; SEM: standard error of the mean; BMI: body mass index; NA: not available; SBP: systolic blood pressure, DBP: diastolic blood pressure; TC: Total Cholesterol; LDL-C: low-
density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG, triglycerides. 
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Table 3: Assessment of risk of bias in the included studies using a checklist based on the Cochrane Risk of Bias Assessment for Randomised 
Trials (with appropriate sections completed for the one cross-sectional study). 
 
Author and 
date 
Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective outcome 
reporting 
Other potential 
threats to 
validity 
Bukowska et al. 
(2006)  
U U L L L U L 
Correa et al. 
(2013)  
U U L L L U L 
Strandhagen et 
al. (2003)  
NA NA L L L U L 
Urgert et al. 
(1996)  
NA NA NA L L U L 
Urgert et al. 
(1997)  
Trial A 
U U L L L U L 
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Urgert et al. 
(1997)  
Trial B 
U U L L L U L 
Urgert et al. 
(1997)  
Trial C 
U U L L L U L 
Urgert et al. 
(1997)  
Trial D 
U U L L H U L 
Yukawa et al. 
(2004)  
 
NA NA L L L U L 
L: low risk of bias; H: high risk of bias; NA: Not applicable; U: unclear risk of bias. 
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Table 4: Summary of the results of studies included in the systematic review 
Study Design Intervention / Exposure Lp(a) at baseline 
mg/dL  
Mean ± S.D. 
unless otherwise 
stated  
Lp(a) at endpoint 
mg/dL  
Mean ± S.D. unless 
otherwise stated  
Summary 
Bukowska et al. (Bukowska et 
al. 2006) 
Randomised 
crossover trial 
Natural coffee  31 ± 27  32  ± 28 No effect of coffee on 
Lp(a) 
No difference between 
groups 
Pressure extracted coffee  32 ± 24 38  ± 26 
Correa et al. (Correa et al. 
2013) 
Crossover Clinical 
Trial 
Medium roast coffee   22 ± 26 
11.5 (median) 
 22 ± 26 
14.0 (median) 
No effect of coffee on 
Lp(a) 
No difference between 
groups 
Medium light roast coffee  22 ± 26 
11.5 (median) 
 23 ± 29 
13.9 (median) 
Strandhagen et al. 
(Strandhagen et al. 2003) 
Controlled Study Filtered coffee  NS -11 (median, 1st 
consumption)*  
Lp(a) reduction during first 
period of coffee 
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-4 (median, 2nd 
consumption) 
consumption. Lp(a) 
increase during second 
abstention period. 
(*P<0.05) 
Abstinence from coffee  NS +2 (median, 1st 
abstention) 
+15 (median, 2nd 
abstention)* 
Urgert et al. (Urgert et al. 
1996) 
Cross-Sectional 
Study 
Boiled coffee drinkers  N/A 13 (0-130) 
Median(range) 
Higher Lp(a) in boiled 
coffee drinkers (P = 0.048) 
Filter coffee drinkers  N/A 7.9 (0-144) 
Median(range) 
Urgert et al. (Urgert 
et al. 1997) 
Trial A Randomised 
Controlled Trial 
Filtered coffee   
20.8 ± 22.3 
9.2 (Median) 
Change from 
baseline: 
+0.2 ± 0.8* 
+0.3 (median)  
Lower Lp(a) in cafetiere 
coffee drinkers than 
filtered coffee drinkers 
(*P<0.05) 
Cafetiere coffee  
15.2 ± 19.9 
9.8 (median) 
Change from 
baseline: 
-2.0 ± 0.8 
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-0.9 (median) 
Urgert et al. (Urgert 
et al. 1997) 
Trial B Randomised 
Controlled Trial 
Placebo oil  
25.9  ± 23.8 
17.2 (median) 
Change from 
baseline: 
+1.1 ± 0.9 
+0.5 
Lower mean and median 
Lp(a) in consumers of 
coffee oil  than consumers 
of placebo oil (**P<0.01) 
Coffee oil   
29.1 ± 32.7 
14.9 (median) 
Change from 
baseline: 
-5.5 ± 1.4** 
-4.8 (median)**  
Urgert et al. (Urgert 
et al. 1997) 
Trial C Randomised 
Controlled Trial 
Placebo oil  
 24.4 ± 23.4 
17.7 (median) 
Change from 
baseline: 
-1.0 ± 1.6 
+0.8 (median) 
Lp(a) lowest in coffee oil 
consuming 
group.(*P<0.05) 
Coffee oil   
16.6 ± 16.6 
9.2 (median) 
Change from 
baseline: 
-4.5 ± 1.3 
-2.3 (median)* 
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Stripped oil   
22.1 ± 25.5 
12.8 (median) 
Change from 
baseline: 
-1.1 ± 1.3 
-0.3 (median) 
Urgert et al. (Urgert 
et al. 1997) 
Trial D Randomised 
Controlled 
Crossover Trial 
Cafestol    
13.9 ± 7.5 
11.5 (median) 
Change from 
baseline: 
-3.5 ± 0.8** 
-3.1 (median)** 
Reduction in both groups 
compared to baseline 
(**P<0.01) 
Cafestol & kahweol    
13.9 ± 7.5 
11.5 (median) 
Change from 
baseline: 
-3.9 ± 1.0** 
-3.5 (median)** 
Yukawa et al. (Yukawa et al. 
2004) 
Controlled Study Coffee   25.1 ± 16.2 23.2 ± 11.4 No effect of coffee on 
Lp(a) 
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FIGURE LEGENDS  
Figure 1.  Flow chart showing the number of studies identified, screened and included in the 
systematic review. 
